类风湿关节炎症状性不良事件的频率:一项探索性在线调查

G. Hazlewood, O. Schieir, V. Bykerk, Kamso Mujaab, P. Tugwell, G. Wells, D. Richards, L. Proulx, Pauline M Hull, S. Bartlett
{"title":"类风湿关节炎症状性不良事件的频率:一项探索性在线调查","authors":"G. Hazlewood, O. Schieir, V. Bykerk, Kamso Mujaab, P. Tugwell, G. Wells, D. Richards, L. Proulx, Pauline M Hull, S. Bartlett","doi":"10.3899/jrheum.210688","DOIUrl":null,"url":null,"abstract":"Objective To generate initial data on the frequency and effect of symptomatic adverse events (AEs) associated with rheumatoid arthritis (RA) drug therapy from the patient perspective. Methods We conducted an exploratory online survey asking patients with RA to indicate whether they currently or had ever experienced the 80 different symptomatic AEs included in the Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Results were summarized to report their frequency, and regression models were used to estimate their associations with RA medication use and overall bother. Results The 560 patients who completed the survey and reported taking ≥ 1 RA medication (disease-modifying antirheumatic drugs [DMARDs], steroids, nonsteroidal antiinflammatory drugs [NSAIDs]), had a mean disease duration of 8 years, and were on a wide range of DMARDs. The number of symptomatic AEs experienced in the past 7 days was none (6%), 1–10 (28%), 11–20 (28%), and > 20 (38%). Overall, most participants reported that side effects bothered them somewhat (28%), quite a bit (24%), or very much (15%). In multivariable regression analyses, current prednisone and NSAID use were associated with the greatest number of current side effects (26 and 22, respectively). Many of the strongest associations between current symptomatic AEs and medication use aligned with known side effect profiles. Conclusion In this exploratory online survey, patients with RA reported frequent symptomatic AEs with their medications that are bothersome. Further work is needed to develop and validate a measure for use in patients with rheumatic disease.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Frequency of Symptomatic Adverse Events in Rheumatoid Arthritis: An Exploratory Online Survey\",\"authors\":\"G. Hazlewood, O. Schieir, V. Bykerk, Kamso Mujaab, P. Tugwell, G. Wells, D. Richards, L. Proulx, Pauline M Hull, S. Bartlett\",\"doi\":\"10.3899/jrheum.210688\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective To generate initial data on the frequency and effect of symptomatic adverse events (AEs) associated with rheumatoid arthritis (RA) drug therapy from the patient perspective. Methods We conducted an exploratory online survey asking patients with RA to indicate whether they currently or had ever experienced the 80 different symptomatic AEs included in the Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Results were summarized to report their frequency, and regression models were used to estimate their associations with RA medication use and overall bother. Results The 560 patients who completed the survey and reported taking ≥ 1 RA medication (disease-modifying antirheumatic drugs [DMARDs], steroids, nonsteroidal antiinflammatory drugs [NSAIDs]), had a mean disease duration of 8 years, and were on a wide range of DMARDs. The number of symptomatic AEs experienced in the past 7 days was none (6%), 1–10 (28%), 11–20 (28%), and > 20 (38%). Overall, most participants reported that side effects bothered them somewhat (28%), quite a bit (24%), or very much (15%). In multivariable regression analyses, current prednisone and NSAID use were associated with the greatest number of current side effects (26 and 22, respectively). Many of the strongest associations between current symptomatic AEs and medication use aligned with known side effect profiles. Conclusion In this exploratory online survey, patients with RA reported frequent symptomatic AEs with their medications that are bothersome. Further work is needed to develop and validate a measure for use in patients with rheumatic disease.\",\"PeriodicalId\":35278,\"journal\":{\"name\":\"The Journal of rheumatology. Supplement\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of rheumatology. Supplement\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3899/jrheum.210688\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of rheumatology. Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3899/jrheum.210688","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 4

摘要

目的从患者角度对类风湿性关节炎(RA)药物治疗相关的症状性不良事件(ae)发生频率和影响进行初步研究。方法:我们进行了一项探索性在线调查,要求RA患者表明他们目前或曾经是否经历过不良事件通用术语标准(PRO-CTCAE)中患者报告的80种不同的症状性不良事件。对结果进行总结以报告其发生频率,并使用回归模型来估计其与RA药物使用和总体麻烦的关系。结果560名完成调查并报告服用≥1种RA药物(改善疾病的抗风湿药物[DMARDs],类固醇,非甾体类抗炎药[NSAIDs])的患者,平均病程为8年,且服用的DMARDs范围广泛。在过去7天内出现症状性不良事件的次数为0(6%)、1-10(28%)、11-20(28%)和bbb20(38%)。总的来说,大多数参与者报告说副作用让他们有些困扰(28%),相当多(24%),或者非常严重(15%)。在多变量回归分析中,目前泼尼松和非甾体抗炎药的使用与目前最大数量的副作用相关(分别为26和22)。目前症状性不良反应与药物使用之间的许多最强关联与已知的副作用概况一致。结论:在这项探索性在线调查中,RA患者报告了频繁的症状性不良反应,这些不良反应伴随着他们的药物治疗。需要进一步的工作来开发和验证用于风湿病患者的测量方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Frequency of Symptomatic Adverse Events in Rheumatoid Arthritis: An Exploratory Online Survey
Objective To generate initial data on the frequency and effect of symptomatic adverse events (AEs) associated with rheumatoid arthritis (RA) drug therapy from the patient perspective. Methods We conducted an exploratory online survey asking patients with RA to indicate whether they currently or had ever experienced the 80 different symptomatic AEs included in the Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Results were summarized to report their frequency, and regression models were used to estimate their associations with RA medication use and overall bother. Results The 560 patients who completed the survey and reported taking ≥ 1 RA medication (disease-modifying antirheumatic drugs [DMARDs], steroids, nonsteroidal antiinflammatory drugs [NSAIDs]), had a mean disease duration of 8 years, and were on a wide range of DMARDs. The number of symptomatic AEs experienced in the past 7 days was none (6%), 1–10 (28%), 11–20 (28%), and > 20 (38%). Overall, most participants reported that side effects bothered them somewhat (28%), quite a bit (24%), or very much (15%). In multivariable regression analyses, current prednisone and NSAID use were associated with the greatest number of current side effects (26 and 22, respectively). Many of the strongest associations between current symptomatic AEs and medication use aligned with known side effect profiles. Conclusion In this exploratory online survey, patients with RA reported frequent symptomatic AEs with their medications that are bothersome. Further work is needed to develop and validate a measure for use in patients with rheumatic disease.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
The Journal of rheumatology. Supplement
The Journal of rheumatology. Supplement Medicine-Medicine (all)
自引率
0.00%
发文量
0
期刊介绍: The Journal of Rheumatology is a monthly international serial edited by Duncan A. Gordon, The Journal features research articles on clinical subjects from scientists working in rheumatology and related fields, as well as proceedings of meetings as supplements to regular issues. Highlights of our 36 years serving Rheumatology include: groundbreaking and provocative editorials such as "Inverting the Pyramid," renowned Pediatric Rheumatology, proceedings of OMERACT and the Canadian Rheumatology Association, Cochrane Musculoskeletal Reviews, and supplements on emerging therapies.
期刊最新文献
Cluster Analysis To Explore Clinical Subphenotypes Of Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss). Feasibility of Conducting Comparative Effectiveness Research and Validation of a Clinical Disease Activity Score for Chronic Nonbacterial Osteomyelitis The Role of Age in Delays to Rheumatological Care in Juvenile Idiopathic Arthritis. Mammalian Target of Rapamycin Pathway Assessment in Antiphospholipid Antibody-Positive Patients with Livedo. Dr. Trefond et al reply: Giant Cell Arteritis After SARS-CoV-2 Vaccination-Coincidence or Trigger ?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1